Pfizer Expects Speedy Integration Of Wyeth, R&D Head Mackay Says
Executive Summary
Pfizer's integration of Wyeth will progress much faster than previous integrations, with "significant announcements" expected within 30 to 60 days after the deal closes, Global R&D Head Martin Mackay said Sept. 22 during Windhover's Pharmaceutical Strategic Alliance Conference in New York City
You may also be interested in...
Pfizer Selects Sites for its Post-Merger Global R&D Network
Newly merged company will cut R&D staff by 15 percent, though timing is unclear.
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011